Medicinal aerosol formulations

• US 5,695,743 A
• Filed: 03/04/1993
• Issued: 12/09/1997
• Est. Priority Date: 12/06/1988
• Status: Expired due to Term

• Current Assignee: 3M Innovative Properties Company (3M Company)
• Original Assignee: Riker Laboratories, Inc. (3M Company)
• Inventors: Greenleaf, David J., Purewal, Tarlochan S.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Benston, Jr., William E.
• Application Number:
  US08/026,476
• Time in Patent Office: 1,741 Days
• Field of Search: 424/489, 424/45, 424/46, 514/291, 514/653
• US Class Current: 424/45
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61K 9/124 characterised by the propellant

Abstract

A self-propelling aerosol formulation which may be free from CFC'"'"'s which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.

Claims

1. An aerosol formulation comprising:

(a) a therapeutically effective amount of a medicament; and

(b) a propellant substantially free of chlorofluorocarbons, said propellant comprising 1,1,1,2-tetrafluoroethane,

said formulation being suitable for delivery to the lung by inhalation.

2. The formulation of claim 1 wherein said medicament is a member selected from the group consisting of salbutamol, beclomethasone dipropionate, disodium cromoglycate, pirbuterol, isoprenaline, adrenaline, rimiterol, and ipratropium bromide.

3. The formulation of claim 1, further comprising (c) a surface active agent.

4. A method for delivering a drug to the lung of a mammal, comprising administering to said mammal an aerosol formulation according to claim 1 by inhalation.

5. A method for treating a mammal having a condition capable of treatment by inhalation, comprising administering to the lung of said mammal an aerosol formulation according to claim 1 by inhalation.